Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 14/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915594 | 1.00 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL916947 | 0.89 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL916945 | 0.89 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL916957 | 0.88 | MAPT (0.63) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL916956 | 0.88 | MAPT (0.63) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL917011 | 0.88 | KDM4E (0.45) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL917010 | 0.88 | KDM4E (0.45) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13673505 | 0.87 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13673506 | 0.87 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL915668 | 0.86 | GUSB (0.44) | MAPTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | disclosed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8148429-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | disclosed |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MELACURE THERAPEUTICS AB (SE) | 2007-04-19 | — | — | US | disclosed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | disclosed |
| EP-1313461-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | Melacure Therapeutics AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | ABL1 486/4885MAPT 4502/4885ALDH1A1 1879/4885 |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | ABL1 466/4885MAPT 4496/4885ALDH1A1 1756/4885 |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | ABL1 486/4885MAPT 4502/4885ALDH1A1 1879/4885 |
| US-20110015437-A1 | USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MC1R, MC5R, MCHR1 | ABL1 486/4885MAPT 4502/4885ALDH1A1 1879/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | ABL1 748/4885MAPT 3465/4885ALDH1A1 1930/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | ABL1 415/4885MAPT 3995/4885ALDH1A1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.